The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of CureVac N.V (NASDAQ: CVAC) was $1.15M for the day, up 2043914% from the previous closing price of $5.49. In other words, the price has increased by $2043914 from its previous closing price. On the day, 2.04 million shares were traded. CVAC stock price reached its highest trading level at $5.55 during the session, while it also had its lowest trading level at $5.41.
Ratios:
Our analysis of CVAC’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.59 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.67. For the most recent quarter (mrq), Quick Ratio is recorded 7.65 and its Current Ratio is at 7.65. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On April 25, 2024, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $12 to $4.
On June 08, 2023, SVB Securities started tracking the stock assigning a Outperform rating and target price of $13.SVB Securities initiated its Outperform rating on June 08, 2023, with a $13 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 07 ’25 when Thaminda Ramanayake bought 6,986 shares for $3.34 per share.
Myriam Mendila bought 17,839 shares of CVAC for $88,019 on Jan 07 ’25. On Jan 07 ’25, another insider, Pierre Kemula, who serves as the affiliate of the company, bought 51,523 shares for $4.93 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CVAC now has a Market Capitalization of 1224865024 and an Enterprise Value of 823915904. As of this moment, CureVac’s Price-to-Earnings (P/E) ratio for their current fiscal year is 6.03. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.13 while its Price-to-Book (P/B) ratio in mrq is 1.75. Its current Enterprise Value per Revenue stands at 1.573 whereas that against EBITDA is 3.421.
Stock Price History:
The Beta on a monthly basis for CVAC is 2.49, which has changed by 0.5677234 over the last 52 weeks, in comparison to a change of 0.09544468 over the same period for the S&P500. Over the past 52 weeks, CVAC has reached a high of $5.72, while it has fallen to a 52-week low of $2.37. The 50-Day Moving Average of the stock is 38.02%, while the 200-Day Moving Average is calculated to be 62.78%.
Shares Statistics:
CVAC traded an average of 1.15M shares per day over the past three months and 3548580 shares per day over the past ten days. A total of 225.16M shares are outstanding, with a floating share count of 95.51M. Insiders hold about 57.58% of the company’s shares, while institutions hold 3.57% stake in the company. Shares short for CVAC as of 1748563200 were 4196958 with a Short Ratio of 3.64, compared to 1745971200 on 4986707. Therefore, it implies a Short% of Shares Outstanding of 4196958 and a Short% of Float of 3.73.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
